Tumor necrosis factor-α and the early vein graft

Journal of Vascular Surgery

Volumn 45, Issue 1, 2007, Pages 169-176

  Jiang, Zhihua ^a,b   Shukla, Ankur ^a,b   Miller, Brett L ^a,b   Espino, Derek R ^a,b   Tao, Ming ^a,b   Berceli, Scott A ^a,b   Ozaki, C Keith ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIAL CIRCULATION; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; GRAFT FAILURE; JUGULAR VEIN; MALE; MORPHOMETRICS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; VEIN GRAFT;

ANIMALS; APOPTOSIS; BLOOD VESSEL PROSTHESIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GRAFT SURVIVAL; HYPERPLASIA; JUGULAR VEINS; MALE; RABBITS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA; UP-REGULATION;

EID: 33845933939     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2006.08.049     Document Type: Article

References (37)

1. Fitzgibbon G.M., Kafka H.P., Leach A.J., Keon W.J., Hooper G.D., and Burton J.R. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 28 (1996) 616-626
2. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 91 (2003) 3A-6A
3. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
4. Sterpetti A.V., Cucina A., Lepidi S., Randone B., Corvino V., D'Angelo L.S., et al. Formation of myointimal hyperplasia and cytokine production in experimental vein grafts. Surgery 123 (1998) 461-469
5. Faries P.L., Marin M.L., Veith F.J., Ramirez J.A., Suggs W.D., Parsons R.E., et al. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. J Vasc Surg 24 (1996) 463-471
6. Jiang Z., Berceli S.A., Pfahnl C.L., Wu L., Goldman D., Tao M., et al. Wall shear modulation of cytokines in early vein grafts. J Vasc Surg 40 (2004) 345-350
7. Kumar A., Dhawan S., Hardegen N.J., and Aggarwal B.B. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 55 (1998) 775-783
8. Gaur U., and Aggarwal B.B. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66 (2003) 1403-1408
9. Tanaka H., Sukhova G., Schwartz D., and Libby P. Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblast growth factor. Arterioscler Thromb Vasc Biol 16 (1996) 12-18
10. Vaday G.G., Hershkoviz R., Rahat M.A., Lahat N., Cahalon L., and Lider O. Fibronectin-bound TNF-alpha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis. J Leukoc Biol 68 (2000) 737-747
11. Rectenwald J.E., Moldawer L.L., Huber T.S., Seeger J.M., and Ozaki C.K. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 102 (2000) 1697-1702
12. Hoefer I.E., van Royen N., Rectenwald J.E., Bray E.J., Abouhamze Z., Moldawer L.L., et al. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. Circulation 105 (2002) 1639-1641
13. Grundmann S., Hoefer I., Ulusans S., van Royen N., Schirmer S.H., Ozaki C.K., et al. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit. Am J Physiol Heart Circ Physiol 289 (2005) H1497-H1505
14. Zhang L., Peppel K., Brian L., Chien L., and Freedman N.J. Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells. Arterioscler Thromb Vasc Biol 24 (2004) 2277-2283
15. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al., ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354 (1999) 1932-1939
16. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
17. Jiang Z., Wu L., Miller B.L., Goldman D.R., Fernandez C.M., Abouhamze Z.S., et al. A novel vein graft model: adaptation to differential flow environments. Am J Physiol Heart Circ Physiol 286 (2004) H240-H245
18. User Bulletin #2. ABI PRISM 7700 Sequence Detection System 2001. Available at: http://dna-9.int-med.uiowa.edu/RealtimePCRdocs/Compar_Anal_Bulletin2.pdf. Accessed Jun 30, 2006.
19. Edwards III C.K., Martin S.W., Seely J., Kinstler O., Buckel S., Bendele A.M., et al. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev 55 (2003) 1315-1336
20. Rosenberg J.J., Martin S.W., Seely J.E., Kinstler O., Gaines G.C., Fukuzuka K., et al. Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon. J Appl Physiol 91 (2001) 2213-2223
21. Porat R., Paddock H.N., Schwaitzberg S.D., Connolly R.J., Wilkens T., Dasch J.R., et al. Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis. Crit Care Med 23 (1995) 1080-1089
22. Gimbrone Jr. M.A., Anderson K.R., Topper J.N., Langille B.L., Clowes A.W., Bercel S., et al. Special communication the critical role of mechanical forces in blood vessel development, physiology and pathology. J Vasc Surg 29 (1999) 1104-1151
23. Gimbrone Jr. M.A., Nagel T., and Topper J.N. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 99 (1997) 1809-1813
24. Surapisitchat J., Hoefen R.J., Pi X., Yoshizumi M., Yan C., and Berk B.C. Fluid shear stress inhibits TNF-alpha activation of JNK but not ERK1/2 or p38 in human umbilical vein endothelial cells: Inhibitory crosstalk among MAPK family members. Proc Natl Acad Sci U S A 98 (2001) 6476-6481
25. Feldman A.M., Combes A., Wagner D., Kadakomi T., Kubota T., Li Y.Y., et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35 (2000) 537-544
26. Zimmerman M.A., Selzman C.H., Reznikov L.L., Miller S.A., Raeburn C.D., Emmick J., et al. Lack of TNF-alpha attenuates intimal hyperplasia after mouse carotid artery injury. Am J Physiol Regul Integr Comp Physiol 283 (2002) R505-R512
27. McComb J., Gould T., Chlipala E., Sennelo G., Frazier J., Kieft G., et al. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. J Rheumatol 26 (1999) 1347-1351
28. Puhakka H.L., Turunen P., Rutanen J., Hiltunen M.O., Turunen M.P., and Yla-Herttuala S. Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. J Vasc Res 42 (2005) 361-367
29. Honda Y., Kitano T., Fukuya F., Sato Y., Iwama S., Morie T., et al. A novel alphavbeta3 integrin antagonist suppresses neointima formation for more than 4 weeks after balloon injury in rats. Arterioscler Thromb Vasc Biol 25 (2005) 1376-1382
30. Schwartz S.M., deBlois D., and O'Brien E.R. The intima. Soil for atherosclerosis and restenosis. Circ Res 77 (1995) 445-465
31. Krasinski K., Spyridopoulos I., Kearney M., and Losordo D.W. In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty. Circulation 104 (2001) 1754-1756
32. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
33. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141-147
34. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov 2 (2003) 736-746
35. Clausell N., Molossi S., Sett S., and Rabinovitch M. In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation 89 (1994) 2768-2779
36. Zhou Z., Lauer M.A., Wang K., Forudi F., Zhou X., Song X., et al. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 161 (2002) 153-159
37. Tartaglia L.A., Pennica D., and Goeddel D.V. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 268 (1993) 18542-18548